triazoles has been researched along with Lupus Erythematosus, Cutaneous, Subacute in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Downie, B; Fleischmann, R; Gurtovaya, O; Matzkies, F; Mozaffarian, A; Pechonkina, A; Robern, M; Tiamiyu, I; Touma, Z; Wallace, D; Werth, VP | 1 |
| Connelly, K; Morand, EF | 1 |
| Burris, K; Fisher, J; Miller, M; Patel, M | 1 |
| Balme, B; Cavailhes, A; Skowron, F; Trancart, M | 1 |
1 trial(s) available for triazoles and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.
Topics: Double-Blind Method; Humans; Janus Kinase Inhibitors; Lupus Erythematosus, Cutaneous; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Treatment Outcome; Triazoles | 2022 |
3 other study(ies) available for triazoles and Lupus Erythematosus, Cutaneous, Subacute
| Article | Year |
|---|---|
Filgotinib in cutaneous lupus: is a negative positive?
Topics: Double-Blind Method; Humans; Lupus Erythematosus, Cutaneous; Protein Kinase Inhibitors; Pyridines; Triazoles | 2022 |
Anastrozole-induced subacute cutaneous lupus erythematosus.
Topics: Aged; Anastrozole; Antibodies, Antinuclear; Arm; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Lupus Erythematosus, Cutaneous; Nitriles; Thorax; Triazoles | 2016 |
Anastrozole-induced subacute cutaneous lupus erythematosus.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Female; Humans; Lupus Erythematosus, Cutaneous; Nitriles; Treatment Outcome; Triazoles | 2008 |